BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
FLX Bio to Present at 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that Brian Wong, M.D., Ph.D., CEO will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 7:30 a.m. Pacific Standard Time in San Francisco, CA. Dr. Wong will provide a corporate update and company overview.
About FLX Bio
FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of best-in-class, oral small molecule therapeutics for the treatment of cancers and other immune disorders. Our lead compounds inhibit the CCR4 pathway which plays a key role in both suppressing the immune response to cancer and in the initiation, progression and persistence of allergic inflammation. We leverage big data and machine learning together with our advanced drug discovery capabilities and deep biology expertise, to develop therapeutics that address key pressure points in pathways that propagate an abnormal immune response.
Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.
For FLX Bio, Inc.
« back to news page